Evidence map›Paper›PMID 27310579›Full record

ArticlePloS one2016

Analysis of Chemokine Receptor Trafficking by Site-Specific Biotinylation.

Marcel Liebick, Christian Schläger, Martin Oppermann

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.3field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Marcel LiebickDepartment of Cellular and Molecular Immunology, University of Göttingen, Göttingen, Niedersachsen, Germany.
Christian SchlägerDepartment of Cellular and Molecular Immunology, University of Göttingen, Göttingen, Niedersachsen, Germany.
Martin OppermannDepartment of Cellular and Molecular Immunology, University of Göttingen, Göttingen, Niedersachsen, Germany.
University of Göttingen · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Chemokine receptors undergo internalization and desensitization in response to ligand activation. Internalized receptors are either preferentially directed towards recycling pathways (e.g. CCR5) or sorted for proteasomal degradation (e.g. CXCR4). Here we describe a method for the analysis of receptor internalization and recycling based on specific Bir A-mediated biotinylation of an acceptor peptide coupled to the receptor, which allows a more detailed analysis of receptor trafficking compared to classical antibody-based detection methods. Studies on constitutive internalization of the chemokine receptors CXCR4 (12.1% ± 0.99% receptor internalization/h) and CCR5 (13.7% ± 0.68%/h) reveals modulation of these processes by inverse (TAK779; 10.9% ± 0.95%/h) or partial agonists (Met-CCL5; 15.6% ± 0.5%/h). These results suggest an actively driven internalization process. We also demonstrate the advantages of specific biotinylation compared to classical antibody detection during agonist-induced receptor internalization, which may be used for immunofluorescence analysis as well. Site-specific biotinylation may be applicable to studies on trafficking of transmembrane proteins, in general.

Indexed as

AmidesAnimalsAntibodies, MonoclonalBasophilsBiotinBiotinylationCarbon-Nitrogen LigasesCCR5 Receptor AntagonistsCell Line, TumorChemokine CCL5Escherichia coli ProteinsGene ExpressionGenetic VectorsMiceProtein TransportQuaternary Ammonium CompoundsAmidesAntibodies, MonoclonalBiotinbirA protein, E coliCarbon-Nitrogen LigasesCCL5 protein, humanCCR5 Receptor AntagonistsChemokine CCL5CXCR4 protein, humanCXCR5 protein, humanEscherichia coli ProteinsQuaternary Ammonium CompoundsRANTES, Met-Receptors, CXCR4Receptors, CXCR5Recombinant Fusion ProteinsRepressor ProteinsTAK 779

Identifiers

PMID27310579
PMCPMC4911081
OpenAlexW2433893828

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.